Do you think drug development groups and clinical researchers would rather have a biomarker discovery tool for neurodegenerative disease that is blood-based or CSF-based? Do you think one biological fluid offers a clear diagnostic advantage over the other?

  • Blood-based biomarkers offer the best opportunity to discover useful biomarkers for neurodegenerative disease
  • CSF-based biomarkers are superior to blood-based biomarkers because the CSF is directly in contact with the CNS
  • Biomarkers from both fluids are valuable for different purposes